Navigation Links
Lutonix Announces Achievement of Significant Milestones and Additions to Executive Leadership Team
Date:6/28/2011

MINNEAPOLIS, June 28, 2011 /PRNewswire/ -- Lutonix today announced receiving approval from the US Food and Drug Administration to begin enrollment in its LEVANT 2 IDE clinical trial for the treatment of peripheral arterial disease (PAD), along with receipt of CE Mark for its drug-coated balloon and ISO certification.  Lutonix is the first company to receive approval from the FDA to initiate a drug-coated balloon trial.  

The company also announced two new additions to its leadership team.  Shawn McCormick was named Chief Operating Officer and will oversee manufacturing, R&D, finance and administration for the company.  Leslie Trigg was named Executive Vice President, Marketing and Commercial Strategy and will oversee all commercialization aspects of the business.

LEVANT 2 Trial Set to Begin

LEVANT 2 is a global, multicenter, randomized study evaluating the safety and efficacy of the Moxy™ Drug Coated Balloon compared to a standard angioplasty balloon for treating diseased leg arteries above the knee.  The trial is designed to support an application to the US FDA for approval of the Moxy balloon.  Co-principal investigators for this international study are Dr. Ken Rosenfield (Massachusetts General Hospital, Boston MA) and Dr. Dierk Scheinert (University of Leipzig, Leipzig Germany).

The LEVANT 2 trial was preceded by LEVANT 1, a multi-center, prospective randomized trial of 101 patients with PAD.  In this study, the Moxy balloon was compared to standard angioplasty.  Data presented during the 2010 Transcatheter Cardiovascular Therapeutics meeting showed that the Moxy balloon had the ability to safely and substantially inhibit restenosis.

"Finding a durable treatment for PAD has proven to be one our most difficult clinical challenges," said Dr. Rosenfield.  "PAD patients are in great need of better treatment options.  This trial is an important step forward
'/>"/>

SOURCE Lutonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lutonix Inc. Announces $20 Million Series B Financing
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 Scott Steiger ... most of the world. As an engineer for the past 20 ... member of the military service. He,s been to six of the ... Photo - http://photos.prnewswire.com/prnh/20141126/161076 Photo - http://photos.prnewswire.com/prnh/20141126/161077 ... for travelers, he has a pretty good idea of what,s required. ...
(Date:11/26/2014)... -- Zynerba Pharmaceuticals , Inc., a specialty pharmaceutical ... cannabinoid treatments, today announced that the company will present ... The conference will be held December 2 to 3, ... York . Zynerba,s Chairman and CEO, Armando ... December 2. To listen to a webcast ...
(Date:11/26/2014)... , Nov. 26, 2014 The ... at a rate of 4%, with world market ... Kalorama Information. MRI and other types of medical ... and treatment of numerous medical conditions in children ... and techniques. Kalorama,s report, Medical Imaging Markets ...
Breaking Medicine Technology:Steiger Has Created the First Pill Case Specifically Designed For Travel 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
(Date:11/28/2014)... 2014 Recently, PrettyTailor.com has developed and ... its customers around the world in celebration of the ... has also launched a special offer on all these ... As a pioneer in the garment industry, PrettyTailor.com brings ... clients large and small. The business carries quite a ...
(Date:11/28/2014)... FL (PRWEB) November 28, 2014 The month ... over 20,000 car accidents occurring in Florida every year ... on the importance of auto insurance policies. , "Optional auto ... drop. Auto insurance is not cheap I know, actually Florida ... the costs are even higher, but what I see is ...
(Date:11/28/2014)... FRIDAY, Nov. 28, 2014 (HealthDay News) -- People with diabetes ... planning can help keep you healthy, an expert says. ... how you,ll deal with the events, the family you,ll be ... the American Association of Diabetes Educators, said in an association ... and still be healthy." One idea is to make ...
(Date:11/28/2014)... MA (PRWEB) November 28, 2014 Agein.com, the ... and advice from some of the foremost experts in the ... for preventing dry skin this winter. , “The official start ... North America has already been hit with an icy blast. ... many are wondering if 2015 will usher in another brutal ...
(Date:11/28/2014)... BambooFlooringChina.com has been recognized as a ... the business has announced its new strand woven ... discount on these new models. , Based on the ... without carpenter machines involved. It is crafted on strand ... for do-it-yourselfers without hard work on installation, also available ...
Breaking Medicine News(10 mins):Health News:2015 Wedding Dresses from PrettyTailor.com Available Now 2Health News:Car Accident Attorney Sean M. Cleary on Auto Insurance Policies Essential for Florida Drivers 2Health News:Holiday Eating Tips for People With Diabetes 2Health News:Agein Corporation, a Leading Anti-Aging Company, Releases Top Diet and Personal Care Tips for Preventing Dry Skin this Season 2Health News:BambooFlooringChina.com Introduces Its New Strand Woven Bamboo Flooring Collection 2
... , Key Highlights, Misys plc (LSE: MSY) ... for the next phase of the turnaround. Misys generated ... to GBP81m,37% ahead of last year. Misys is executing ... the turnaround plan, building a platform for growth., ...
... Wake Forest University Baptist Medical Center demonstrates emergency room ... heart attack, even when laboratory tests haven,t yet confirmed ... called i*trACS, and analyzed patients with heart attack symptoms ... participating U.S. centers. , The findings were released ...
... and Naturalization ready at Passport ... ... vaccine requirements will affect,anyone who is applying for an immigrant visa ... permanent residence. Applicants,must show proof of vaccinations against vaccine-preventable diseases, as,recommended ...
... in scrotum boosts sperm count, motility, study finds , , ... invasive procedure can treat a common cause of male ... baby, a new study finds. , The condition, called ... the scrotum which prevents the normal circulation of blood ...
... LOS ANGELES, July 23 Times may be tough, ... nothing like,a dazzling new smile to boost confidence. Cosmetic ... in on success, citing his,experience that a beautiful smile ... agreement is Landon Brown, who is now sporting a ...
... person had heart trouble, the worse their performance , , WEDNESDAY, ... coronary heart disease seem to fare worse on measures of ... heart disease, the worse the performance in such mental processes ... in the July 23 issue of the European Heart ...
Cached Medicine News:Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 2Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 3Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 4Health News:Study shows emergency physicians have good first instincts in diagnosing heart attacks 2Health News:USCIS Tightens Vaccination Requirements 2Health News:Simple Procedure Improves Male Fertility 2Health News:Simple Procedure Improves Male Fertility 3Health News:Rock The Cradle's Bad Boy Landon Brown Owes His Irresistible New Smile to Dr. Michael Kosdon 2Health News:Coronary Disease Dulls Cognitive Skills 2
... Infinity Triglycerides powder reagent once reconstituted ... of single liquid stability to help ... and provide quick result turnaround time. ... Triglycerides powder reagent provides a long ...
... single liquid stable reagent offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The patented ... provides a long shelf life that ...
... Infinity Creatinine single liquid stable reagent ... of single liquid stability to help ... and provide quick result turnaround time. ... Creatinine reagent provides a long shelf ...
... Amylase powder reagent once reconstituted offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... powder reagent provides a long shelf ...
Medicine Products: